Forbion Capital Fund Iil Cooperatief U.A investment portfolio

Akarna Therapeutics is a biotechnology company developing novel therapies for non‑alcoholic steatohepatitis (NASH) and other liver diseases, targeting patients who suffer from these conditions.

Enterprise Therapeutics is a clinical‑stage biopharmaceutical company that discovers and develops novel therapies for respiratory diseases, including cystic fibrosis, asthma and COPD. Its focus is on muco‑regulatory treatments that target ion channels such as ENaC to increase mucus hydration and clearance, thereby reducing lung infections and improving patient quality of life.